Mercy Hospital & Health Services Contact Us
About Mercy
Join Our Team
set font size large set font size medium set font size small
email this page print this page
Timi Banner

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications (SAVOR- TIMI 53)

Sponsor: AstraZeneca


Type 2 Diabetes MellitusDrug: Saxagliptin
Drug: Placebo
Phase IV

ArmsAssigned Interventions
Saxagliptin: ExperimentalDrug: Saxagliptin
5 mg or 2.5 mg once daily
Placebo: Placebo ComparatorDrug: Placebo

Detailed Description:

A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes



Ages Eligible for Study: 40 Years and older

Genders Eligible for Study: Both

Accepts Healthy Volunteers: No


Inclusion Criteria:
  • Patients with type 2 diabetes mellitus
  • HbA1c ≥6.5%. (based on the last measured and documented laboratory measurement within 6 months)
  • High risk for CV events -Established cardiovascular disease and/or multiple risk factors
Exclusion Criteria:
  • Current or previous (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics
  • Acute vascular event <2months prior to randomisation


Ameer Kabour, MD
Tarif Kanaan, MD

Michelle Hickam, RN, BSN
Brenda Hoagland, RN, CCRC
Julie Neidhardt, RN, BSN

Please contact us at 419-251-4919 for further information about this study.


Mercy Saved My Life
Mary R. has been a Mercy employee for 20 years and loves her job as a Registration Specialist, but ...
Read the full story >

Share Your Moment! >

follow us online
facebook youtube

Contact us
Home  |  Sitemap

Disclaimer & Terms of Use  |  Privacy Statement  |  Notice of Privacy Practices
Copyright ©2015 Mercy. Last modified 10/29/2010